Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement : a study of the Chronic Malignancies Working Party of EBMT
(2022) In Bone Marrow Transplantation 57(3). p.416-422- Abstract
Allogeneic hematopoietic cell transplantation (allo-HCT) is the only curative treatment for patients with myeloid/lymphoid neoplasm (MLN) with FGFR1 rearrangement, but data on overall results are limited. We report on the largest series of patients (n = 22) with FGFR1-rearranged MLN undergoing allo-HCT. Distribution according to cytogenetic subtype was: t(8;13) in 11 cases, t(8;22) in 7 cases, t(6;8) in 2 cases, and other (n = 2). Over a third of patients displayed a chronic myeloproliferative (MPN) phenotype, another third showed MPN features with concomitant lymphoma or acute leukemia, and the remaining ones presented as acute leukemia. After a median follow-up of 4.1 years from transplant, the estimated 5-year survival rate,... (More)
Allogeneic hematopoietic cell transplantation (allo-HCT) is the only curative treatment for patients with myeloid/lymphoid neoplasm (MLN) with FGFR1 rearrangement, but data on overall results are limited. We report on the largest series of patients (n = 22) with FGFR1-rearranged MLN undergoing allo-HCT. Distribution according to cytogenetic subtype was: t(8;13) in 11 cases, t(8;22) in 7 cases, t(6;8) in 2 cases, and other (n = 2). Over a third of patients displayed a chronic myeloproliferative (MPN) phenotype, another third showed MPN features with concomitant lymphoma or acute leukemia, and the remaining ones presented as acute leukemia. After a median follow-up of 4.1 years from transplant, the estimated 5-year survival rate, progression-free survival, non-relapse mortality and relapse incidence was 74%, 63%, 14% and 23%, respectively. Causes of death were relapse/progression (n = 4), graft-versus-host disease (n = 2) and organ toxicity (n = 1). Six patients experienced disease relapse at a median of 6.1 months (range: 2.3–119.6). Two of them achieved complete remission with ponatinib or pemigatinib and were alive at 34.5 and 37 months from relapse, respectively. These data highlight the significant curative potential of allo-HCT in this aggressive disease. Maintenance with tyrosine kinase inhibitors may be a promising approach, at least in cases with detectable residual disease after transplant.
(Less)
- author
- publishing date
- 2022
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Bone Marrow Transplantation
- volume
- 57
- issue
- 3
- pages
- 7 pages
- publisher
- Nature Publishing Group
- external identifiers
-
- scopus:85123506613
- pmid:35066569
- ISSN
- 0268-3369
- DOI
- 10.1038/s41409-021-01553-x
- language
- English
- LU publication?
- no
- id
- 39d47eea-fb02-4cb5-b270-66e956b83178
- date added to LUP
- 2022-04-08 12:16:51
- date last changed
- 2024-06-09 03:00:51
@article{39d47eea-fb02-4cb5-b270-66e956b83178,
abstract = {{<p>Allogeneic hematopoietic cell transplantation (allo-HCT) is the only curative treatment for patients with myeloid/lymphoid neoplasm (MLN) with FGFR1 rearrangement, but data on overall results are limited. We report on the largest series of patients (n = 22) with FGFR1-rearranged MLN undergoing allo-HCT. Distribution according to cytogenetic subtype was: t(8;13) in 11 cases, t(8;22) in 7 cases, t(6;8) in 2 cases, and other (n = 2). Over a third of patients displayed a chronic myeloproliferative (MPN) phenotype, another third showed MPN features with concomitant lymphoma or acute leukemia, and the remaining ones presented as acute leukemia. After a median follow-up of 4.1 years from transplant, the estimated 5-year survival rate, progression-free survival, non-relapse mortality and relapse incidence was 74%, 63%, 14% and 23%, respectively. Causes of death were relapse/progression (n = 4), graft-versus-host disease (n = 2) and organ toxicity (n = 1). Six patients experienced disease relapse at a median of 6.1 months (range: 2.3–119.6). Two of them achieved complete remission with ponatinib or pemigatinib and were alive at 34.5 and 37 months from relapse, respectively. These data highlight the significant curative potential of allo-HCT in this aggressive disease. Maintenance with tyrosine kinase inhibitors may be a promising approach, at least in cases with detectable residual disease after transplant.</p>}},
author = {{Hernández-Boluda, Juan Carlos and Pereira, Arturo and Zinger, Nienke and Gras, Luuk and Martino, Rodrigo and Paneesha, Shankara and Finke, Jürgen and Chinea, Anabelle and Rambaldi, Alessandro and Robin, Marie and Saccardi, Riccardo and Natale, Annalisa and Snowden, John A. and Tsirigotis, Panagiotis and Vallejo, Carlos and Wulf, Gerald and Xicoy, Blanca and Russo, Domenico and Maertens, Johan and Daguindau, Etienne and Lenhoff, Stig and Hayden, Patrick and Czerw, Tomasz and McLornan, Donal P. and Yakoub-Agha, Ibrahim}},
issn = {{0268-3369}},
language = {{eng}},
number = {{3}},
pages = {{416--422}},
publisher = {{Nature Publishing Group}},
series = {{Bone Marrow Transplantation}},
title = {{Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement : a study of the Chronic Malignancies Working Party of EBMT}},
url = {{http://dx.doi.org/10.1038/s41409-021-01553-x}},
doi = {{10.1038/s41409-021-01553-x}},
volume = {{57}},
year = {{2022}},
}